Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The e

Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T,  Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026

Three income buckets and eight holdings can close the gap between your current savings and a five-figure monthly paycheck, but the math behind each yield level reveals a trade-off most investors never think to calculate.

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an inv

Most retirees lean on Social Security as their primary income, but a dividend portfolio sized correctly could double that monthly check entirely. The catch is that choosing the wrong yield tier could cost you hundreds of thousands of dollars or quietly erode your principal over time.

Simon Property Group and Agree Realty offer 4%+ yields and double-digit total return potential amid sector pullbacks from rising bond yields. SPG's A-rated balance sheet, accelerating NOI, and raised FFO guidance position it well despite $2B in 2024 debt maturities and volatile rates. ADC's investment-grade tenant focus, long-term ground leases, low leverage, and insider buying support its resilience and 4.7% well-covered monthly yield.

Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:

The 10-year Treasury yield just hit a year-long high and dragged every one of these net lease REITs down with it, but falling share prices and failing dividends are not the same thing, and the difference matters more right now

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California. World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.